^
    Back
    Association details:
    Biomarker:ALK fusion + ALK V1180L
    Cancer:Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Lung Cancer
    Title:

    Transformation of NSCLC to SCLC harboring EML4–ALK Fusion with V1180L mutation after alectinib resistance and response to lorlatinib: a case report and literature review

    Published date:
    10/25/2023
    Excerpt:
    We present a case of alectinib-induced transformation from ALK-positive NSCLC to SCLC with an ALK V1180L mutation after acquiring alectinib resistance….Pathological and genetic analyses indicated the transformation to pulmonary small cell carcinoma accompanied by ALK fusion V1180L mutation....After taking lorlatinib for 5 months, the lesions continue to shrink...
    DOI:
    https://doi.org/10.1016/j.lungcan.2023.107415